Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01629667 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
A Phase 2 study, sponsored by MedImmune.
- Terminated
- Registry status
- Phase 2
- Development phase
- 409
- Enrollment target
NCT01629667 is a Phase 2 study that was terminated before completion, run by MedImmune. The registered enrollment target is 409 participants.
The verdict
NCT01629667, a Phase 2 study, was terminated before completion, sponsored by MedImmune.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 409 participants
- Enrollment target
Study Summary
To study the safety and effectiveness of multiple-doses of tralokinumab on pulmonary function in adults with mild to moderate idiopathic pulmonary fibrosis (IPF). IPF is a chronic, progressive, irreversible, and usually fatal lung disease of unknown cause.
Interventions
- OTHER Placebo
- BIOLOGICAL Tralokinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 409 participants |
| Start Date | 2012-10 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01629667
The ClinicalTrials.gov registry entry for NCT01629667 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 409 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01629667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01629667 about?
NCT01629667 is a clinical study titled "A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis". To study the safety and effectiveness of multiple-doses of tralokinumab on pulmonary function in adults with mild to moderate idiopathic pulmonary fibrosis (IPF). IPF is a chronic, progressive, irreversible, and usually fatal lung disease of unknown cause.
What is the current status of trial NCT01629667?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 409 participants. The study started on 2012-10. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01629667?
The interventions under investigation include: Placebo (OTHER), Tralokinumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01629667?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.